🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Advanced/Metastatic Colorectal Adenocarcinoma

Ph II Study of Enfortumab Vedotin in Patients With Advanced or Metastatic CRC or HCC NCT06553885Phase 21 site📍 Tampa H. Lee Moffitt Cancer Center and Research Institute · Tests: Enfortumab Vedotin Advanced Therapies for Liver Metastases NCT04622423n/a1 site📍 Milan IRCCS San Raffaele AB122 Platform Study NCT04999761Phase 19 sites📍 Aichi📍 Chiba📍 Ehime Taiho Pharmaceutical Co., Ltd. · Tests: AB122, AB122, TAS-116, TAS-120, TAS-115 A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy NCT06362369Phase 1, Phase 25 sites📍 Aurora📍 Lake Mary📍 Lebanon 7 Hills Pharma, LLC · Tests: Alintegimod, Ipilimumab, Nivolumab BBO-11818 in Adult Subjects With KRAS Mutant Cancer NCT06917079Phase 117 sites📍 Los Angeles📍 Sacramento📍 San Diego TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) · Tests: BBO-11818, Pembrolizumab, Platinum chemotherapy (cisplatin or carboplatin), Pemetrexed, Cetuximab A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-8989 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutations NCT07610798Phase 1, Phase 21 site📍 Guangzhou Shenzhen Ionova Life Sciences Co., Ltd. · Tests: INV-8989 A Study to Learn More About How Safe BAY 3771249 is and How Well it Works in People With Advanced or Metastatic Colorectal Cancer That Has a KRAS G12D Mutation NCT07535112Phase 121 sites📍 Phoenix📍 Duarte📍 San Diego Bayer · Tests: BAY 3771249, Cetuximab GM103 Intratumoral Injection in Patients With Locally Advanced, Unresectable, Refractory and/or Metastatic Solid Tumors NCT06265025Phase 1, Phase 24 sites📍 Goyang-si📍 Seoul📍 Seoul GeneMedicine Co., Ltd. · Tests: GM103 (Part A), GM103 (Part B), GM103 and Pembrolizumab (Part C) A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors NCT06983743Phase 19 sites📍 Santa Rosa📍 Aurora📍 Sarasota Erasca, Inc. · Tests: ERAS-0015, ERAS-0015 in combination Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors NCT06040541Phase 117 sites📍 Sacramento📍 New Haven📍 Sarasota Revolution Medicines, Inc. · Tests: RMC-9805, RMC-6236 A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations NCT06835569Phase 114 sites📍 Orlando📍 Tampa📍 Boston Alterome Therapeutics, Inc. · Tests: ALTA3263, cetuximab, mFOLFOX6, Pembrolizumab, Pemetrexed + Cisplatin /Carboplatin Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors NCT06218914Phase 118 sites📍 Duarte📍 Los Angeles📍 Newport Beach AstraZeneca · Tests: NT-112: Autologous, engineered T Cells targeting KRAS G12D, AZD0240: Autologous, engineered T Cells targeting KRAS G12D Study of IBI3028 in Participants With Locally Advanced, Unresectable, or Metastatic Solid Tumors NCT07589205Phase 11 site📍 Tianjin Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. · Tests: Drug: IBI3028 A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression NCT06682793Phase 1, Phase 210 sites📍 Gilbert📍 La Jolla📍 Los Angeles A2 Biotherapeutics Inc. · Tests: A2B395, xT CDx with HLA-LOH assay Early Detection of Advanced Adenomas and Colorectal Cancer NCT06342440n/a6 sites📍 Monrovia📍 San Diego📍 Dalian City of Hope Medical Center · Tests: DENEB A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors NCT04657068Phase 1, Phase 288 sites📍 Birmingham📍 Scottsdale📍 Little Rock Artios Pharma Ltd · Tests: ART0380, Gemcitabine, Irinotecan A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors NCT07020117Phase 114 sites📍 Duarte📍 Irvine📍 Miami Aktis Oncology, Inc. · Tests: [225Ac]Ac-AKY-1189 (therapeutic), [64Cu]Cu-AKY-1189 (imaging) AVA6103 in Subjects With Locally Advanced or Metastatic Selected Solid Tumors NCT07454642Phase 17 sites📍 Scottsdale📍 Sarasota📍 Chicago Avacta Life Sciences Ltd · Tests: AVA6103 Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program NCT06265285Phase 21 site📍 Jacksonville Mayo Clinic · Tests: Home Health Encounter, Nivolumab, Patient Monitoring, Questionnaire Administration A Phase 1 Dose Escalation and Dose Expansion Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation NCT07458347Phase 19 sites📍 Los Angeles📍 Sarasota📍 Tampa Kestrel Therapeutics, Inc. · Tests: KST-6051, Gemcitabine/nab-paclitaxel, Cetuximab, Pembrolizumab, mFOLFOX6 A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements NCT03093116Phase 1, Phase 2165 sites📍 Duarte📍 Glendale📍 La Jolla Turning Point Therapeutics, Inc. · Tests: Oral repotrectinib (TPX-0005) A Phase 1 Study of TGI-5 as Monotherapy and in Combination With Nivolumab in Subjects With Locally Advanced/Metastatic Solid Tumors NCT07376707Phase 11 site📍 Shanghai Hefei TG ImmunoPharma Co., Ltd. · Tests: TGI-5 Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates NCT07292298Phase 23 sites📍 Aurora📍 Rochester📍 Portland University of Colorado, Denver · Tests: High Rare Dose Rectal Brachytherapy Boost CDH17 CAR-T Therapy in Advanced Malignant Solid Tumors NCT06937567EARLY Phase 11 site📍 Hangzhou Zhejiang University · Tests: CDH17 CAR-T, FAST LACO-Stim CDH17 CAR-T A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors NCT07094204Phase 122 sites📍 Santa Monica📍 Atlanta📍 Jefferson Astellas Pharma Inc · Tests: ASP5834, panitumumab Dual-Target CAR-NK Cells for Biomarker-Selected Advanced Colorectal Cancer NCT07462650Phase 1, Phase 21 site📍 Shenzhen Beijing Biotech · Tests: EB-DUO-CAR-NK-CEA/GCC (IV) A Study of MGC026 in Participants With Advanced Solid Tumors NCT06242470Phase 112 sites📍 Los Angeles📍 Grand Rapids📍 Lake Success MacroGenics · Tests: MGC026 Dose Escalation, MGC026 Dose for Expansion, Pembrollizumab, vobramitamab tavatecan A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation NCT06179160Phase 134 sites📍 Phoenix📍 Palo Alto📍 Santa Monica Incyte Corporation · Tests: INCB161734, Cetuximab, Retifanlimab, GEMNabP, mFOLFIRINOX A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors NCT06657144Phase 130 sites📍 Tucson📍 Duarte📍 Aurora Coherus Oncology, Inc. · Tests: CHS-114, Toripalimab, 5 Fluorouracil, Cisplatin Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of WEF-001 as Monotherapy in Advanced KRAS-Mutant Solid Tumours. NCT07148128Phase 1, Phase 24 sites📍 Dallas📍 San Antonio📍 Toronto Auricula Biosciences Inc. · Tests: WEF-001
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy